Neuroregeneration and repair

Molecular Neuropharmacology

Group leader:
Olga Pol Rigau
Olga.Pol@uab.cat
TEL: 619 757 054
Group members:

Andrés Díaz
Sara Polo
Patricia Moreno
Sergi Leánez
STRATEGIC OBJECTIVES

Our main objective is to investigate new strategies for the treatment of the arthritic and neuropathic pain, as well as of the emotional disorders associated to chronic pain by using pharmacological, molecular and genetic approaches.

MAIN RESEARCH LINES

- **New therapeutic targets in inflammatory and neuropathic pain.** Identify new drug combinations suited to alleviate inflammatory, arthritic, and/or neuropathic pain by using different animal pain models and investigate the mechanism of action of these analgesic drugs.

- **New strategies for the treatment of diabetic neuropathy.** Identify new approaches to reverse diabetic neuropathy, one of the major complications associated with diabetes, by evaluating the therapeutic action of specific molecules in animal models of diabetes.

- **Neuropharmacology of opioids and cannabinoids.** Establish new strategies to improve the analgesic effects produced by opioids and cannabinoids in chronic pain and avoid the development of side effects resulting from the administration of high and/or continued doses of these drugs.

- **Modulation of the emotional responses associated with pain.** Investigate the role played by gaseous neurotransmitters in the modulation of the emotional disorders associated to the development of chronic pain.

FEATURED PUBLICATIONS


- Hervera A, Leánez S, Motterlini R, Pol O. Treatment with Carbon Monoxide-releasing Molecules and an HO-


See more O. Pol in PubMed.